Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In the United States, more than 30,000 cases of mpox (formerly known as monkeypox) had occurred as of March 1, 2023, in an outbreak disproportionately affecting transgender persons and gay, bisexual, and other men who have sex with men. In 2019, the JYNNEOS vaccine was approved for subcutaneous administration (0.5 ml per dose) to prevent mpox infection. On August 9, 2022, an emergency use authorization was issued for intradermal administration (0.1 ml per dose); however, real-world effectiveness data are limited for either route. METHODS: We conducted a case-control study based on data from Cosmos, a nationwide Epic electronic health record (EHR) database, to assess the effectiveness of JYNNEOS vaccination in preventing medically attended mpox disease among adults. Case patients had an mpox diagnosis code or positive orthopoxvirus or mpox virus laboratory result, and control patients had an incident diagnosis of human immunodeficiency virus (HIV) infection or a new or refill order for preexposure prophylaxis against HIV infection between August 15, 2022, and November 19, 2022. Odds ratios and 95% confidence intervals were estimated from conditional logistic-regression models, adjusted for confounders; vaccine effectiveness was calculated as (1 - odds ratio for vaccination in case patients vs. controls) × 100. RESULTS: Among 2193 case patients and 8319 control patients, 25 case patients and 335 control patients received two doses (full vaccination), among whom the estimated adjusted vaccine effectiveness was 66.0% (95% confidence interval [CI], 47.4 to 78.1), and 146 case patients and 1000 control patients received one dose (partial vaccination), among whom the estimated adjusted vaccine effectiveness was 35.8% (95% CI, 22.1 to 47.1). CONCLUSIONS: In this study using nationwide EHR data, patients with mpox were less likely to have received one or two doses of JYNNEOS vaccine than control patients. The findings suggest that JYNNEOS vaccine was effective in preventing mpox disease, and a two-dose series appeared to provide better protection. (Funded by the Centers for Disease Control and Prevention and Epic Research.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
Flanagan, B. E., Hallisey, E. J., Adams, E. E., & Lavery, A. M. (2018) · PubMed · Cited by 480
Real-world effectiveness of a single dose of mpox vaccine in males
Wolff Sagy, Y., Zucker, R., Hammerman, A., Markovits, H., Arieh, N. G., Abu Ahmad, W., Battat, E., Ramot, N., Carmeli, G., Mark-Amir, A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02229-3 · Cited by 195
Frey, S. E., Wald, A., Edupuganti, S., Jackson, L. A., Stapleton, J. T., Sahly, H. M. E., El‐Kamary, S. S., Edwards, K. M., KEYSERLING, H. L., Winokur, P. L., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.06.075 · Cited by 144
Intradermal Vaccination for Monkeypox — Benefits for Individual and Public Health
Brooks, J. T., Marks, P. W., Goldstein, R. H., & Walensky, R. P. (2022) · New England Journal of Medicine · doi:10.1056/nejmp2211311 · Cited by 57
Hughes, K., Middleton, D. B., Nowalk, M. P., Balasubramani, G. K., Martin, E. T., Gaglani, M., Talbot, H. K., Patel, M. M., Ferdinands, J. M., Zimmerman, R. K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1927 · Cited by 38
Metadata
- Authors
- Deputy, N. P., Deckert, J., Chard, A. N., Sandberg, N., Moulia, D. L., Barkley, E., Dalton, A. F., Sweet, C., Cohn, A. C., Little, D. R., Cohen, A. L., Sandmann, D., Payne, D. C., Gerhart, J. L., & Feldstein, L. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-06-29
- Volume
- 388
- Issue
- 26
- Pages
- 2434-2443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4377010965
- Cited by
- 305
- References
- 6
- FWCI
- 36.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.